Please Note: This trial is no longer enrolling new participants
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
| Protocol No. | PHO-NOVARTIS-CCTL019G2201J | Scope | National |
|---|---|---|---|
| Principal Investigator | April Rahrig | Treatment Type | Treatment |
| Age Group | Children | Phase | Phase II |
